bariatric surgery vs glp-1 Metabolic vs. Receptor Agonists for Obesity Management Bariatric Surgery vs GLP-1 Medications
Description
Pfizer has said it expects pills to eventually capture about a third of the obesity drug market, which is predicted to grow to about $130 billion by the end of the decade.
GLP-1 medications offer metabolic benefits for many patients, but specific contraindications and risk factors determine who should not use them
Discover how Gila monster venom and GLP-1 led to breakthrough diabetes treatments
reductions vs GLP-1 RAs ranged from 1.68 kg with tirzepatide 5 mg to 7.16 kg with tirzepatide 15 mg
Recent evidence suggests these drugs also benefit heart, kidney, liver, and even brain health.
